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with advanced NSCLC. Vandetanib targets clinically validated signal-
ing pathways in NSCLC by inhibiting VEGFR-dependent tumor angio-
genesis and EGFR-dependent tumor growth and survival. Vandetanib 
also inhibits RET kinase activity, which is an important growth driver 
in certain types of thyroid cancer. 
Phase I evaluation in patients with advanced solid tumors showed 
vandetanib was generally well tolerated at daily oral doses of ≤300 mg. 
Common adverse events included rash, diarrhea and asymptomatic QTc 
prolongation, all of which were controlled by standard management. A 
series of randomized, double-blind Phase II studies have investigated 
the efﬁcacy of vandetanib in NSCLC, both as monotherapy and in 
combination with certain chemotherapies. A two-part study compared 
vandetanib (300 mg) with geﬁtinib (IRESSA™; 250 mg) in 2nd/3rd-
line NSCLC (in part B, eligible patients had the option to switch to 
the alternative treatment). The study achieved its primary efﬁcacy 
objective: median progression-free survival (PFS) in part A was 11 
weeks for vandetanib versus 8 weeks for geﬁtinib (HR=0.69, 95% CI 
= 0.50-0.96; 1-sided P=0.013). In 2nd-line NSCLC, vandetanib (100 
or 300 mg) or placebo was assessed in combination with docetaxel. 
This study also achieved its primary objective, with vandetanib 100 
mg + docetaxel demonstrating a signiﬁcant prolongation of PFS versus 
docetaxel alone (HR=0.64, 95% CI = 0.38-1.05; 1-sided P=0.037). In 
1st-line NSCLC, vandetanib (300 mg/day) ± carboplatin and paclitaxel 
(CP) was compared with CP + placebo. The primary objective was met, 
with vandetanib + CP prolonging PFS versus CP alone (HR=0.76, 95% 
CI = 0.50-1.15; 1-sided P=0.098): median PFS was 24 weeks (vande-
tanib + CP) and 23 weeks (CP). The vandetanib monotherapy arm was 
stopped early after a planned interim PFS analysis met the criterion 
for discontinuation (HR >1.33 vs CP). In all three studies, no overall 
survival beneﬁt with vandetanib was seen. However, overall survival 
was a secondary endpoint in these studies and the effect of vandetanib 
on survival is potentially confounded by the impact of post-progression 
therapies.
The positive outcomes from the Phase II studies have led to the initia-
tion of Phase III evaluation of vandetanib in a broad population of pa-
tients with advanced NSCLC, including squamous and non-squamous 
cell histology (Table). Clinical development is also ongoing in other 
tumor types, including hereditary medullary thyroid cancer, where 
encouraging antitumor activity has been observed.







Vandetanib versus placebo in patients previously treated with 
anti-EGFR therapy (6474IL0044) 300 Overall survival
Vandetanib versus erlotinib in refractory NSCLC (6474IL0057) 300 PFS
Combination regimens 
Vandetanib + docetaxel in 2nd-line NSCLC (6474IL0032) 100 PFS
Vandetanib + pemetrexed in 2nd-line NSCLC (6474IL0036) 100 PFS
PD3-3-5 Molecular Targeted Therapy: Beyond EGFR Inhibitors, Thu, 12:30 - 14:15
Outcomes for elderly advanced stage non-small cell lung 
cancer (NSCLC) patients (pts) treated with bevacizumab (B) in 
combination with carboplatin (C) and paclitaxel (P): Analysis of 
Eastern Cooperative Oncology Group (ECOG) 4599 study 
Ramalingam, Suresh S.1 Dahlberg, Suzanne E.2 Langer, Corey J.3 Gray, 
Robert2 Belani, Chandra P.1 Brahmer, Julie R.4 Sandler, Alan5 Schiller, 
Joan H.6 Johnson, David H.5 
1 University of Pittsburgh, Pittsburgh, PA, USA 2 Dana Farber Cancer 
Institute, Boston, MA, USA 3 Fox Chase Cancer Center, Philadelphia, 
PA, USA 4 Johns Hopkins University, Baltimore, MD, USA 5 Vander-
bilt-Ingram Cancer Center, Nashville, TN, USA 6 University of Texas 
Southwestern Medical Center, Dallas, TX, USA 
Background: PC administered in combination with bevacizumab 
extends survival for advanced non-squamous NSCLC pts. Based on 
SEER data, elderly pts (age ≥ 70 years) represent > 50% of all new 
cases of lung cancer and present unique therapeutic challenges. The 
ECOG 4599 database was analyzed to compare the outcomes in elderly 
pts treated with PCB vs. PC alone.
Methods: Pts ≥ 70 years at study entry constituted the elderly cohort. 
Each arm (PCB vs. PC) and age group (≥ 70 vs. < 70) was compared 
with respect to baseline pt characteristics, response rate (RR), progres-
sion-free survival (PFS), survival and toxicity.
Results: Out of 850 eligible pts, 26% (N=224) were ≥ 70 years of age 
(1.6% > 80 years). Median age for the elderly was 74 yrs; 44% were 
≥ 75 yrs. Baseline characteristics of the elderly cohort were similar to 
the younger group except for a higher proportion of males (62% vs. 
52%, P = 0.005). For the elderly pts, there was a trend towards superior 
response rate (29% vs. 17%, P = 0.067) and median PFS (5.9 mos vs. 
4.9 mos, P = 0.063) with PCB when compared to PC, though there was 
no difference in overall survival (PCB = 11.3 mos; PC = 12.1 mos; 
P=0.4). Grades 3-5 toxicities (CTC version 2.0) were noted in 87% of 
elderly pts treated with PCB compared to 61% with PC (P < 0.001). 
Treatment-related death rates with PCB vs. PC were 6.3% vs. 1.8% 
(NS) for the elderly. Febrile neutropenia (6% vs. 0.9%), proteinuria 
(8% vs. 0) and hypertension (6% vs. 0.9%) were more common with 
PCB than PC among the elderly. When compared to younger pts, the 
elderly experienced more neutropenia (34% vs. 22%), bleeding (7.9% 
vs. 3.2%), proteinuria (7.9% vs. 1.3%), muscle weakness (7.9% vs. 
2.2%) and motor neuropathy (3.5% vs. 0.6%) with PCB.
Conclusions: The proportion of elderly patients in ECOG 4599 is the 
highest recorded among ECOG phase III studies for advanced NSCLC. 
Increased toxicity with the addition of bevacizumab in those ≥ 70 yrs 
may have contributed to the absence of survival beneﬁt for PCB vs PC, 
but this observation is limited by its post-hoc, retrospective nature.
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